ArticleBMC research notes2025
Optimizing resazurin-based viability assays for P-MSC/TER308 cell line to enhance results reliability.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing Cell Density and Unveiling Cytotoxic Profiles of DMSO and Ethanol in Six Cancer Cell Lines: Experimental and In Silico Insights.Methods and protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe results of this research contribute to the LifeSaver project, which focuses on reducing neonatal and infant mortality resulting from preterm births. The project aims to create an in vitro system simulating prenatal conditions to screen and analyze chemicals and pharmaceuticals, establishing scientifically justified regulations for their use during pregnancy. Because several papers have recently identified data inconsistencies in pre-clinical studies, a key part of the project involves optimizing cellular cytotoxicity assays to enhance the reliability of pharmacological and toxicity screening for drugs and environmental contaminants.
resultsThe resazurin-based viability assay was chosen as the primary method due to its widespread adoption and simplicity in assessing drug cytotoxicity. This work describes the optimization of the resazurin-based viability assay on the P-MSC/TERT308 cell line, a placenta-derived mesenchymal stem cell used within the LifeSaver project. By applying our previously described and validated Standard Operating Procedure, we fine-tuned experimental parameters, consistently obtaining reliable results with measurement uncertainty of less than 10%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.